Abstract
Objectives: Increased glucose levels in diabetics result in advanced glycation endproduct (AGE)-modifications of plaque components. This is considered as an important course of the increased cardiovascular disease in diabetic patients. Immune responses against AGE-modified LDL are associated with cardiovascular disease in diabetic individuals. Methylglyoxal (MGO) is a reactive aldehyde forming AGE. MGO arise from oxidation of glucose, but may also be formed from fatty acid oxidation. We asked if autoantibodies against MGO-modified epitopes of the LDL-protein apoB100 could predict cardiovascular events in a cohort consisting mainly of non-diabetic individuals.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
